HomeCompareADVM vs BTI

ADVM vs BTI: Dividend Comparison 2026

ADVM yields 45.87% · BTI yields 5.38%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ADVM wins by $279.9K in total portfolio value
10 years
ADVM
ADVM
● Live price
45.87%
Share price
$4.36
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$317.6K
Annual income
$60,065.20
Full ADVM calculator →
BTI
BTI
● Live price
5.38%
Share price
$58.47
Annual div
$3.15
5Y div CAGR
11.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$37.7K
Annual income
$2,786.64
Full BTI calculator →

Portfolio growth — ADVM vs BTI

📍 ADVM pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodADVMBTI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ADVM + BTI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ADVM pays
BTI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ADVM
Annual income on $10K today (after 15% tax)
$3,899.08/yr
After 10yr DRIP, annual income (after tax)
$51,055.42/yr
BTI
Annual income on $10K today (after 15% tax)
$457.40/yr
After 10yr DRIP, annual income (after tax)
$2,368.64/yr
At 15% tax rate, ADVM beats the other by $48,686.78/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ADVM + BTI for your $10,000?

ADVM: 50%BTI: 50%
100% BTI50/50100% ADVM
Portfolio after 10yr
$177.7K
Annual income
$31,425.92/yr
Blended yield
17.69%
📊

Analyst Conviction Gap

Where Wall Street is split right now

ADVM
Analyst Ratings
10
Buy
6
Hold
Consensus: Buy
Price Target
$4.83
+10.8% upside vs current
Range: $4.00 — $5.50
Altman Z
-32.7
Piotroski
1/9
BTI
Analyst Ratings
12
Buy
4
Hold
2
Sell
Consensus: Buy
Price Target
$40.00
-31.6% upside vs current
Range: $40.00 — $40.00
Altman Z
2.1
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ADVM buys
0
BTI buys
0
No recent congressional trades found for ADVM or BTI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricADVMBTI
Forward yield45.87%5.38%
Annual dividend / share$2.00$3.15
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%11.3%
Portfolio after 10y$317.6K$37.7K
Annual income after 10y$60,065.20$2,786.64
Total dividends collected$248.2K$14.3K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyBuy
Analyst price target$4.83$40.00

Year-by-year: ADVM vs BTI ($10,000, DRIP)

YearADVM PortfolioADVM Income/yrBTI PortfolioBTI Income/yrGap
1← crossover$15,287$4,587.16$11,299$598.92+$4.0KADVM
2$22,911$6,553.70$12,794$703.91+$10.1KADVM
3$33,694$9,179.50$14,518$829.07+$19.2KADVM
4$48,670$12,616.75$16,513$978.64+$32.2KADVM
5$69,108$17,032.01$18,827$1,157.84+$50.3KADVM
6$96,549$22,602.46$21,518$1,373.12+$75.0KADVM
7$132,818$29,511.17$24,657$1,632.46+$108.2KADVM
8$180,057$37,941.48$28,329$1,945.74+$151.7KADVM
9$240,732$48,070.97$32,637$2,325.33+$208.1KADVM
10$317,648$60,065.20$37,708$2,786.64+$279.9KADVM

ADVM vs BTI: Complete Analysis 2026

ADVMStock

Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.

Full ADVM Calculator →

BTIConsumer Staples

British American Tobacco p.l.c. provides tobacco and nicotine products to consumers in the Americas, Europe, the Asia-Pacific, the Middle East, Africa, and the United States. It offers vapour, heated, and modern oral nicotine products; combustible cigarettes; and traditional oral products, such as snus and moist snuff. The company provides its products under the Vuse, glo, Velo, Grizzly, Kodiak, Dunhill, Kent, Lucky Strike, Pall Mall, Rothmans, Newport, Natural American Spirit, and Camel brands. The company distributes its products to retail outlets. British American Tobacco p.l.c. was founded in 1902 and is based in London, the United Kingdom.

Full BTI Calculator →
📬

Get this ADVM vs BTI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ADVM vs SCHDADVM vs JEPIADVM vs OADVM vs KOADVM vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.